FDA issued a Warning Letter to Shilpa Medicare Limited on 10/9/2020 as a result of this inspection.
FDA investigators audited the Shilpa Medicare - Polepally, Jadcherla, India facility and issued inspectional observations (via FDA 483) on 25 Feb 2020.
Product details
- Category: Human Drugs
- Inspection end: 25 Feb 2020
- Location: Polepally, Jadcherla, India
- FEI: 3009876430
